Potassium voltage-gated channel subfamily B member 1 (Kv2.1) (Kv2.1)

Potassium voltage-gated channel subfamily B member 1 (Kv2.1) is a major pore-forming subunit of the delayed rectifier potassium channel, primarily expressed in the central nervous system and pancreatic beta cells (UniProt P15387). It plays a critical role in regulating the frequency and duration of action potentials by mediating the efflux of potassium ions during repolarization (PubMed: 25132138). In neurons, Kv2.1 is unique for its localization in large clusters on the soma and proximal dendrites, where it influences neuronal excitability and integrates synaptic inputs (PubMed: 24945598). Mutations in the encoding KCNB1 gene are linked to developmental and epileptic encephalopathy, highlighting its importance in brain development and function (NIH: Genetic Home Reference). Beyond the nervous system, Kv2.1 is involved in glucose-stimulated insulin secretion, making it a potential target for metabolic disorders (PubMed: 19416711). Pharmacological modulation of Kv2.1 is being explored for treating epilepsy and neuroprotection, though selectivity remains a challenge due to its structural similarity to other potassium channels (IUPHAR/BPS Guide to Pharmacology).

Other names

KCNB1Delayed rectifier potassium channel 1DRK1Voltage-gated potassium channel subunit Kv2.1

Drugs targeting Kv2.1 typically act as pore blockers or gating modifiers to either inhibit or enhance the delayed rectifier potassium current, thereby modulating cellular membrane potential and excitability (IUPHAR/BPS Guide to Pharmacology).